SOM BIOTECH
 
You are here: Home Corporate Information Team

Team

 
Raúl Insa, MD, PhD, MBA linkedin
Founder & CEO
Raúl is Physician by training, obtained high-honors and an extraordinary prize for his PhD in Clinical Neurology, holds an MBA from ESADE Business School, and attended  some Executive Education Programs at IESE and Harvard Business Schools. For more than 20 years he has been working in high responsibility positions at Parke-Davis (now Pfizer), UCB Pharma, Uriach Group (now Palau Pharma) and ISDIN (Esteve Group).  His commitment to SOM is full and exclusive.

Núria Gavaldà, BSc, PhD linkedin
Chief Scientific Officer
Núria holds a PhD in Biology, cum-Ladue by the School of Medicine, University of Barcelona. She has worked in the Department of Pharmacology and Cellular Biology of the University of Barcelona, before leaving to UK, where she has been for 5 years at the University of Cardiff, School of Biosciences (Wellcome Trust Foundation grant). In Cardiff she has conducted research work in basic neuroscience and has specialized in Project Management
 
Núria Reig, BSc, PhD linkedin
Chief Knowledge Officer
PhD in Biochemistry and Molecular Biology from the UB, cum laude and Special Award for her promotion. She worked 6 years at the Ecole Polytechnique Fédérale de Lausanne (Switzerland), where she shared 50% of her time at Yale University (CT, USA) in research areas related to bacterial pathogenesis and immunology. During two years she worked at Xigen SA, a  Swiss biotechnology company specialized in inflammation, with the position of Senior Scientist in Discovery Research.  
 
Oscar Huertas, BSc linkedin
Chief Technology Officer
Oscar joined SOM in 2012. He holds a degree in Chemistry from the University of Barcelona and a degree in Biochemistry from the University Autonoma de Barcelona, post-graduate degree in Computational Chemistry. He worked 3 years in Intelligent Pharma as Research Scientist developing projects of computational chemistry in different areas. He is responsible for the company drug discovery computerized system.
.
Santiago Esteva, BSc, PhD linkedin
Head of Scientific Operations

David Harrison, BSc linkedin
Junior Scientist

Innova 31  linkedin
Chief Financial Officer
 

Hot News

Repurposing drugs; more than $20Billion in sales
September, 2012

A recent Thomson Reuters report indicates that drug repositioning is expected to generate up to $20Billion in annual sales during 2012, thus opening up a new source of revenue to large, medium and small Pharma companies.
 
 
SOM Biotech in New European Economy
Winter, 2012

SOM Biotech, has been identified as one of the best opportunities to invest in start-up biopharmaceuticals companies in Catalonia. Link:  http://www.neweuropeaneconomy.com/home-mainmenu-51/fdi-mainmenu-59/514-adding-value-to-existing-drugs
 
SOM0226 presented at the XIIIth International Symposium on Amyloidosis

May 6th-10th, 2012

SOM0226, a reprofiled drug for the treatment of TTR amyloidosis, has been presented at the XIIIth International Symposium on Amyloidosis in Groningen, The Netherlands. The product has been recognized as one of the most promising in-coming therapies by the scientific expert community in the field.

 

BIOINCUBADORA

innova31

logo_biocat_rgb

asebio

Ministerio de Sanidad

CDTI

ENISA

ACC1O

NEWS